Virpax Pharmaceuticals, Inc. Common Stock
VRPX
VRPX was delisted on the 3rd of April, 2025.
10 hedge funds and large institutions have $493K invested in Virpax Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
17% less funds holding
Funds holding: 12 → 10 (-2)
40% less capital invested
Capital invested by funds: $828K → $493K (-$334K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$661 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$94.5K |
| 2 |
Renaissance Technologies
New York
|
-$16.1K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$12.9K |
| 4 |
QPW
Quantum Private Wealth
Tampa,
Florida
|
-$10.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $234K | -$94.5K | -429 | -27% |
|
2
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $80.7K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $57K | -$16.1K | -73 | -20% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $52.1K | – | – | – |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $51.2K | -$1.76K | -8 | -3% |
|
6
Northern Trust
Chicago,
Illinois
| $12.2K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $4.98K | +$661 | +3 | +14% |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $479 | – | – | – |
|
9
BlackRock
New York
| $371 | – | – | – |
|
10
Morgan Stanley
New York
| $120 | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $94 | – | – | – |
|
12
Wells Fargo
San Francisco,
California
| $50 | – | – | – |
|
|
TSS
13
Two Sigma Securities
New York
| – | -$12.9K | -48 | Closed |
|
|
QPW
14
Quantum Private Wealth
Tampa,
Florida
| – | -$10.8K | -40 | Closed |
|
VRPX Hedge Fund Activity: Q3 2023 in Review
10 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Virpax Pharmaceuticals, Inc. Common Stock (VRPX) for Q3 2023, worth a combined $493K — down 40% from $828K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VRPX and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $661. The largest seller was Sabby Management, cutting an estimated $94.5K.
- 10 institutional investors held Virpax Pharmaceuticals, Inc. Common Stock (VRPX) as of Q3 2023, down from 12 in Q2 2023.
- Funds reported $493K of Virpax Pharmaceuticals, Inc. Common Stock stock for Q3 2023, down 40% quarter-over-quarter.
- 0 funds opened new Virpax Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 2 closed out, a net change of -2 holders.
- The largest Virpax Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Tower Research Capital (TRC), an estimated $661 added.
- The largest Virpax Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was Sabby Management, an estimated $94.5K sold.
Based on aggregated 13F filings for Q3 2023.